News Releases Year: All News201920182017201620152014201320122011 Items per page All News2550 November 13, 2019 Summary ToggleAllena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update Read more November 7, 2019 Summary ToggleAllena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206 Read more October 17, 2019 Summary ToggleAllena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting Read more September 16, 2019 Summary ToggleAllena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria Read more September 11, 2019 Summary ToggleAllena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase Read more August 29, 2019 Summary ToggleAllena Pharmaceuticals to Participate in Upcoming Investor Conferences in September Read more August 7, 2019 Summary ToggleAllena Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update Read more August 6, 2019 Summary ToggleAllena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference Read more June 27, 2019 Summary ToggleAllena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock Read more June 21, 2019 Summary ToggleAllena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria Workshop Read more Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
